



(51) International Patent Classification:
C40B 30/04 (2006.01)

(21) International Application Number:
PCT/US2011/055656

(22) International Filing Date:
10 October 2011 (10.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/391,558 8 October 2010 (08.10.2010) US

(72) Inventors; and

(71) Applicants : **WILLIAMS, John** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US). **DON-ALDSON, Josh** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US). **HORNE, David** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US). **MA, Yulong** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US). **ZER, Cindy** [US/US]; 1500 E. Duarte Road, Duarte, California

91010-3000 (US). **BZYMEK, Krzysztof** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US). **AVERY, Kendra** [US/US]; 1500 E. Duarte Road, Duarte, California 91010-3000 (US).

(74) Agent: **SLIGER, Lauren**; Perkins Coie LLP, P.O. Box 1208, Patent - LA, Seattle, Washington 98111-1208 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

(54) Title: A MONOCLONAL ANTIBODY FRAMEWORK BINDING INTERFACE FOR MEDITOPES, MEDITOPE DELIVERY SYSTEMS AND METHODS FOR THEIR USE

Figure 4 A-B



(57) Abstract: An antibody framework binding interface for the cyclic meditoes C-QFDLSTRRLK-C (cQFD; SEQ ID NO:1) and C-QYNLSSRALK-C (cQYN; SEQ ID NO:2) and methods for their use are provided herein. In one embodiment, a binding interface is formed by a framework region, and not a complementarity determining region (CDR), of an antibody or functional fragment thereof. In another embodiment, a therapeutic human or humanized antibody has one or more human framework residues replaced with one or more corresponding murine residues such that a meditope having the sequence cQFD or cQYN stably binds the one or more human framework residues.



UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*